Details of Disease

Disease Name

Diabetic complication

Disease Class

5A2Y: Acute diabete complication

Disease Hierarchy

DIS01GPL: Grass pollen hypersensitivity

DIS4S2FC: Diabetic complication

ICD-11

ICD-11: 5A2Y

ICD-9

ICD-9: 253.5, 588.1

Expand ICD-11

'5A14

Expand ICD-10

'E14; 'E14.0; 'E14.1; 'E14.2; 'E14.3; 'E14.4; 'E14.5; 'E14.6; 'E14.7; 'E14.8; 'E14.9

Expand ICD-9

253.5,588.1

General Information of Disease (ID: DIS4S2FC)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 45 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Acarbose	DMRM3AW	Approved	Small molecular drug	[1]
Acetohexamide	DMR6N7H	Approved	Small molecular drug	[2]
Becaplermin	DM1R5X4	Approved	NA	[3]
Biphasic porcine insulin	DME969E	Approved	NA	[4]
Colestilan	DMD1RQK	Approved	Small molecular drug	[4]
DermaGraft	DMX7WLN	Approved	NA	[4]
Desmopressin	DMS3GVE	Approved	Small molecular drug	[5]
Glibenclamide	DM8JXPZ	Approved	Small molecular drug	[6]
Gliclazide	DMN6QO5	Approved	Small molecular drug	[7]
Glimepiride	DM5FSJA	Approved	Small molecular drug	[8]
Glipizide	DMZA5PQ	Approved	Small molecular drug	[9]
Gliquidone	DMB0EUX	Approved	Small molecular drug	[10]
Glisolamide	DMMJXGV	Approved	Small molecular drug	[4]
Glycodiazine	DM1WL9O	Approved	Small molecular drug	[11]
HL-001	DMO4O3W	Approved	NA	[4]
Human insulin zinc suspension	DMU0SK3	Approved	NA	[4]
Human neutral insulin	DMA5OBU	Approved	Small molecular drug	[4]
Insulin	DMB7CE0	Approved	NA	[12]
Insulin determir	DM79NZ5	Approved	NA	[4]
Insulin Lyspro recombinant	DM5XHVR	Approved	NA	[13]
Insulin recombinant	DMYVP5G	Approved	Small molecular drug	[13]
Insulin Susp Isophane Recombinant Human	DMW8KI7	Approved	NA	[4]
Insulin Susp Protamine Zinc Beef/Pork	DM0NATE	Approved	NA	[4]
Insulin Zinc Susp Recombinant Human	DM6MO9X	Approved	NA	[4]
Insulin, porcine	DMO95XI	Approved	Small molecular drug	[13]
Insulin-aspart	DMX7V28	Approved	Small molecular drug	[13]
Insulin-glargine	DMR4HIW	Approved	Small molecular drug	[14]
Insulin-glulisine	DMQI0FU	Approved	NA	[15]
Insulin-lispro	DM4O90W	Approved	Small molecular drug	[13]
Metreleptin	DM1NOEK	Approved	NA	[16]
Miglitol	DMXBQAM	Approved	Small molecular drug	[17]
Mitiglinide	DMP8HEL	Approved	Small molecular drug	[18]
Nateglinide	DMLK2QH	Approved	Small molecular drug	[19]
Pioglitazone	DMKJ485	Approved	Small molecular drug	[20]
Porcine isophane insulin	DMJUXSC	Approved	NA	[4]
Pulmonary insulin	DMFDKU1	Approved	NA	[4]
Repaglinide	DM5SXUV	Approved	Small molecular drug	[21]
Sarpogrelate	DMGLP6S	Approved	Small molecular drug	[22]
Setmelanotide	DMPVRN9	Approved	NA	[23]
Soluble insulin	DMPQJT3	Approved	NA	[4]
Tolazamide	DMIHRNA	Approved	Small molecular drug	[24]
Triproamylin acetate	DM7QZAZ	Approved	NA	[4]
Troglitazone	DM3VFPD	Approved	Small molecular drug	[25]
Uridine triacetate	DM1WYDU	Approved	Small molecular drug	[26]
Voglibose	DMUBP9O	Approved	Small molecular drug	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 45 Drug(s)

This Disease is Treated as An Indication in 74 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CDR-134F194	DM7ME07	IND submitted	NA	[27]
Acadesine	DM1RMF5	Phase 3	Small molecular drug	[28]
AIR-insulin	DM8SYTE	Phase 3	NA	[29]
Cetilistat	DMWAHTN	Phase 3	Small molecular drug	[30]
Fidarestat	DMZL1I8	Phase 3	Small molecular drug	[31]
Gemigliptin	DMZKGPV	Phase 3	Small molecular drug	[32]
GLP-1	DMR6YH3	Phase 3	NA	[33]
MK-0431C	DM9H075	Phase 3	NA	[34]
NN5401	DM0QV27	Phase 3	NA	[35]
SAR342434	DMR0EWV	Phase 3	NA	[36]
SaxaDapa FDC	DMAPRWV	Phase 3	NA	[37]
Sf-1019	DMHPYAJ	Phase 3	NA	[4]
INCB13739	DMLQ3PO	Phase 2a	Small molecular drug	[38]
ADMVA	DM819CO	Phase 2	Vaccine	[39]
AVE-2268	DMA42BV	Phase 2	NA	[40]
AZD1656	DMUE90I	Phase 2	Small molecular drug	[41]
BRL 35135	DMLFGHX	Phase 2	Small molecular drug	[42]
CBX-129801	DMSBNTZ	Phase 2	NA	[43]
CP-331684	DMVO5DR	Phase 2	Small molecular drug	[44]
CT-1	DM4U350	Phase 2	NA	[45]
DS-8500	DMUXIRM	Phase 2	NA	[46]
Eligen insulin	DMI7S3X	Phase 2	NA	[47]
GK1-399	DMLFSMX	Phase 2	NA	[48]
Imeglimin	DMMQFG2	Phase 2	Small molecular drug	[49]
ISIS-GCCR	DMICMNU	Phase 2	Antisense drug	[50]
ISIS-GCGR	DMHNYWP	Phase 2	Antisense drug	[51]
LIDORESTAT	DMA0RI9	Phase 2	Small molecular drug	[52]
LY-2599506	DMMI0RH	Phase 2	NA	[53]
LY-295501	DMTAM2Q	Phase 2	Small molecular drug	[54]
LY-518674	DMBM2I9	Phase 2	Small molecular drug	[55]
LY2944876	DML6XWR	Phase 2	NA	[56]
M-16209	DMZ7YX3	Phase 2	Small molecular drug	[57]
Naveglitazar	DMD0E8U	Phase 2	Small molecular drug	[58]
NNC-0123-0000-0338	DMDTNOS	Phase 2	NA	[59]
NOX-E36	DMHG3UR	Phase 2	NA	[60]
NRX-4204	DMYXOU2	Phase 2	Small molecular drug	[61]
ONO-5129	DMFX3P1	Phase 2	NA	[62]
P-1736	DMEYQPN	Phase 2	NA	[63]
PF-04991532	DM94NBE	Phase 2	NA	[64]
PRX00933	DM1JNDV	Phase 2	NA	[65]
SLx-4090	DMM3AI8	Phase 2	Small molecular drug	[66]
TRC-4186	DM2S2A7	Phase 2	NA	[67]
ZD2079	DMTYD8Q	Phase 2	Small molecular drug	[68]
ORE-1001	DM471ZH	Phase 1/2	Small molecular drug	[69]
TTP-814	DMH9RGV	Phase 1/2	NA	[70]
AC 165198	DMS3915	Phase 1	NA	[71]
Adjustable basal insulin	DMQVEZB	Phase 1	NA	[72]
AZD5658	DMV6DF3	Phase 1	NA	[73]
AZD7687	DMS9I6A	Phase 1	Small molecular drug	[74]
AZD8329	DMTD57A	Phase 1	Small molecular drug	[75]
BMS-196085	DMTZ3A6	Phase 1	Small molecular drug	[76]
CDR-134D123	DMG80HI	Phase 1	NA	[77]
CM3.1-AC100	DMSJVX3	Phase 1	NA	[78]
DS-7309	DM7C4U9	Phase 1	NA	[79]
Figopitant	DMLH2Q6	Phase 1	Small molecular drug	[80]
HL-018	DMT3HKZ	Phase 1	NA	[81]
HPP-593	DMUA4XM	Phase 1	NA	[82]
Insulin adjustable basal	DMAHXI7	Phase 1	NA	[72]
MK-4074	DM74JHW	Phase 1	NA	[83]
NM504	DM7X99Z	Phase 1	NA	[84]
NN-1218	DMDGCHR	Phase 1	NA	[85]
P-7435	DMNZQU5	Phase 1	NA	[86]
SAR164653	DMQ98MW	Phase 1	NA	[87]
SAR425899	DM53IPE	Phase 1	NA	[88]
SBS-1000	DMXU2GS	Phase 1	NA	[89]
SDZ-FOX-988	DMLMAG4	Phase 1	Small molecular drug	[90]
TAK-329	DMMWNQP	Phase 1	NA	[91]
TTP-547	DMYFUOP	Phase 1	NA	[92]
ZD7114	DMZQP7N	Phase 1	Small molecular drug	[68]
ZP2929	DMRVDUM	Phase 1	NA	[93]
ZY01	DMSLPTO	Phase 1	NA	[94]
ZYGK-1	DM4IG16	Phase 1	NA	[95]
ZYOG1	DMZ6042	Phase 1	NA	[94]
PMID22911925C2	DM5UWH3	Clinical trial	Small molecular drug	[96]
------------------------------------------------------------------------------------


⏷ Show the Full List of 74 Drug(s)

This Disease is Treated as An Indication in 63 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Phenformin	DMQ52JG	Withdrawn from market	Small molecular drug	[97]
EF-4	DMKYVSE	Discontinued in Preregistration	NA	[98]
IMIRESTAT	DM8KSMX	Discontinued in Phase 3	Small molecular drug	[99]
MINALRESTAT	DM86XJG	Discontinued in Phase 3	Small molecular drug	[100]
Ponalrestat	DM04ZUW	Discontinued in Phase 3	Small molecular drug	[101]
AD-5467	DMM02XV	Discontinued in Phase 2	Small molecular drug	[102]
AZD2207	DM1TDWI	Discontinued in Phase 2	Small molecular drug	[103]
Bimoclomol	DMOP95G	Discontinued in Phase 2	Small molecular drug	[104]
BM-17.0249.2NA	DMRYQ8W	Discontinued in Phase 2	NA	[105]
BTS-67582	DM54K2P	Discontinued in Phase 2	NA	[106]
CASTANOSPERMINE	DMPZFDE	Discontinued in Phase 2	Small molecular drug	[107]
Deriglidole	DMYJ28R	Discontinued in Phase 2	Small molecular drug	[108]
HL-1225	DM1SAR3	Discontinued in Phase 2	NA	[109]
JTT-811	DMJ1ZTB	Discontinued in Phase 2	NA	[110]
PSN-9301	DMMF9RS	Discontinued in Phase 2	NA	[111]
Pyrazinoylguanidine	DMD308S	Discontinued in Phase 2	NA	[112]
Reglixane	DMIN73Y	Discontinued in Phase 2	NA	[113]
S-15261	DMLCYX8	Discontinued in Phase 2	Small molecular drug	[114]
T-1095	DMGFS51	Discontinued in Phase 2	Small molecular drug	[115]
Teglicar	DMPCRUT	Discontinued in Phase 2	Small molecular drug	[116]
TEI-6122	DM3F5E0	Discontinued in Phase 2	Small molecular drug	[117]
TPM-02/Insulin	DMGICCO	Discontinued in Phase 2	NA	[118]
TS-033	DMALIFO	Discontinued in Phase 2	NA	[119]
TTP-355	DMCEGN4	Discontinued in Phase 2	NA	[120]
ZOPOLRESTAT	DMWOT92	Discontinued in Phase 2	Small molecular drug	[121]
AZD-8677	DMJNBQY	Discontinued in Phase 1	NA	[122]
AZD1175	DM65MUI	Discontinued in Phase 1	NA	[123]
Basulin	DM28NBY	Discontinued in Phase 1	NA	[124]
BAY-73-7977	DMKJ3IA	Discontinued in Phase 1	NA	[125]
DS-6930	DMDAO8E	Discontinued in Phase 1	NA	[126]
DS-7250	DMQK53O	Discontinued in Phase 1	NA	[127]
FT-105	DMDW64X	Discontinued in Phase 1	NA	[124]
GR-79236	DM9C1LQ	Discontinued in Phase 1	Small molecular drug	[128]
NN344	DM3XPUI	Discontinued in Phase 1	NA	[129]
PF-2575799	DM2VN3N	Discontinued in Phase 1	NA	[130]
PF-4325667	DMCA7Q1	Discontinued in Phase 1	NA	[131]
RO-16-8714	DMOVZDY	Discontinued in Phase 1	Small molecular drug	[132]
SDZ-CPI-975	DM70MJQ	Discontinued in Phase 1	Small molecular drug	[133]
TAK-100	DMH16ND	Discontinued in Phase 1	Small molecular drug	[134]
A-717	DMIQHSI	Terminated	NA	[140]
ALT-946	DM7V9YL	Terminated	Small molecular drug	[141]
AZD-7545	DMU6L4I	Terminated	Small molecular drug	[142]
AZM-090	DM5BDWT	Terminated	NA	[143]
AZM-145	DMEF79V	Terminated	NA	[144]
BM-13.1180	DMKFSJB	Terminated	NA	[145]
BM-13.1188	DMAYU3U	Terminated	NA	[146]
BM-13.1196	DMC8W2G	Terminated	NA	[147]
BM-13677	DMKITQN	Terminated	Small molecular drug	[148]
BM-17.0505	DMMOFWQ	Terminated	NA	[149]
CLX-0301	DMVUL4P	Terminated	NA	[150]
DARGLITAZONE	DM6IGRL	Terminated	Small molecular drug	[151]
DSP-7238	DMAE43P	Terminated	NA	[152]
Emeriamine	DMTT6NN	Terminated	Small molecular drug	[153]
FR-62765	DMJS9YB	Terminated	Small molecular drug	[154]
JTT-608	DMZBNHC	Terminated	Small molecular drug	[155]
NCP-004	DM1O46Q	Terminated	NA	[156]
PL-611	DMMMRMK	Terminated	NA	[157]
SB-219994	DMCZDE9	Terminated	Small molecular drug	[158]
Sipoglitazar	DM5SBUJ	Terminated	NA	[159]
SPR-210	DMTGIUV	Terminated	Small molecular drug	[160]
TER-16998	DMQIYZR	Terminated	NA	[161]
TH-0318	DMSRDGE	Terminated	NA	[162]
WF-2421	DMBMOI6	Terminated	Small molecular drug	[163]
------------------------------------------------------------------------------------


⏷ Show the Full List of 63 Drug(s)

This Disease is Treated as An Indication in 5 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ARI-809	DM61TDB	Preclinical	Small molecular drug	[135]
CLX-090700	DMV6GZ0	Preclinical	NA	[136]
FR-79620	DMXR287	Preclinical	Small molecular drug	[137]
JD-5037	DMTGI64	Preclinical	NA	[138]
MC-1002	DMSQ4CV	Preclinical	NA	[139]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 61 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
A-76341	DMT9N1I	Investigative	NA	[164]
AA-10044	DM66FGP	Investigative	NA	[165]
AMPE4L	DM64X25	Investigative	NA	[166]
AMPPL	DMVHOQE	Investigative	NA	[167]
AMPSL	DMXRIUT	Investigative	NA	[167]
Aom-0925	DMZQ54Z	Investigative	NA	[165]
APX-002	DMJUOPP	Investigative	NA	[165]
BCL-5	DMDSUIA	Investigative	NA	[165]
BetaGRAFT	DM7AOC2	Investigative	NA	[165]
BPI-713001	DMP0ZEA	Investigative	NA	[165]
CDR-267F018	DMKBEHS	Investigative	NA	[165]
CO-8	DMU433B	Investigative	NA	[165]
CP-70949	DMBQTZG	Investigative	NA	[168]
CT-12441	DMS7KXZ	Investigative	Small molecular drug	[165]
CVT-12012	DMOCKMZ	Investigative	Small molecular drug	[169]
CWF-07pre03	DM2N28H	Investigative	NA	[165]
CZ-MD001	DMUEY9W	Investigative	NA	[165]
D-420720	DM048OG	Investigative	NA	[170]
DG-770	DM9DGLG	Investigative	NA	[165]
DRA-161	DMWD8MQ	Investigative	NA	[165]
DwLIP-GCGRrx	DMW9GT7	Investigative	Small molecular drug	[101]
EDL-2000	DMHF3XO	Investigative	NA	[165]
EM-2198	DMFNCO5	Investigative	NA	[165]
EMC-0901	DMUH1JX	Investigative	NA	[170]
EQ-1280	DM2KMNU	Investigative	NA	[171]
ESI-014	DMJXLVF	Investigative	NA	[165]
ETR-002	DM7O8G3	Investigative	NA	[165]
F-18 exendin-4 derivative PET tracers	DMHETZN	Investigative	NA	[166]
FMP-825	DMW5V9U	Investigative	NA	[172]
GFT-1229	DMRJNC0	Investigative	NA	[165]
GKA-23	DMIENSW	Investigative	NA	[173]
GPCR39 pepducins	DM1W5G9	Investigative	NA	[174]
GX-G6	DM1RY6Q	Investigative	Antibody	[175]
JNJ-28165722	DMZ3Z5S	Investigative	NA	[165]
KY-021	DM7HYB3	Investigative	NA	[165]
L-168049	DM3UGMD	Investigative	Small molecular drug	[176]
LL-6531	DM6RCES	Investigative	NA	[177]
MKG-02	DME9CKA	Investigative	NA	[165]
MLR-1326	DMK8EEC	Investigative	NA	[165]
MS-806	DMBSU4I	Investigative	NA	[165]
Ndx-Peptide	DMPQCBR	Investigative	NA	[165]
PD-4048	DM0OEH3	Investigative	NA	[178]
PD-4074	DM4BDEY	Investigative	NA	[179]
PEGylated insulin	DMMNETM	Investigative	NA	[165]
PGC GLP-1	DM0NBKR	Investigative	NA	[175]
Pro-Islet	DM8KMA0	Investigative	NA	[165]
PSN-101	DMUROIY	Investigative	Small molecular drug	[180]
Quick-acting insulin	DM9YWG8	Investigative	NA	[181]
R-954	DM6Y9P7	Investigative	NA	[182]
RAGE-Fc fusion protein	DMEPGWP	Investigative	NA	[165]
Recombinant human zinc alpha-2 glycoprotein (ZAG)	DMUEQLT	Investigative	NA	[165]
ReSX-i	DM21CPG	Investigative	NA	[165]
RHIIP	DMWP09B	Investigative	NA	[183]
SB-36131	DMHWKOJ	Investigative	NA	[165]
SCD-211	DM3G712	Investigative	NA	[165]
TGFTX-2	DMKUHH5	Investigative	NA	[165]
Tgth-0100	DMB45KE	Investigative	NA	[165]
UAI-101	DM9AKE5	Investigative	NA	[165]
Vapill	DM30E56	Investigative	NA	[184]
ZP-3022	DMJ16AD	Investigative	NA	[175]
[123I] iodobenzoyl 12-Ex4	DMHWNOS	Investigative	NA	[166]
------------------------------------------------------------------------------------


⏷ Show the Full List of 61 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6791).
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6793).
3	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2182).
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2414).
7	Cefradine - FDA approved drug information (drug label) from DailyMed.
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6820).
9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6821).
10	Drug information of Gliquidone, 2008. eduDrugs.
11	Coupling between proximal tubular transport processes. Studies with ouabain, SITS and HCO3-free solutions. Pflugers Arch. 1977 Apr 25;368(3):245-52.
12	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5012).
13	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
14	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7572).
15	2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
16	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7333).
17	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4842).
18	Drug information of Mitiglinide, 2008. eduDrugs.
19	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6833).
20	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2694).
21	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6841).
22	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 210).
23	2011 Pipeline of Ipsen.
24	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6847).
25	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2693).
26	ClinicalTrials.gov (NCT02110147) Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria. U.S. National Institutes of Health.
27	Clinical pipeline report, company report or official report of CSIR-Central Drug Research Institute.
28	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5133).
29	Clinical pipeline report, company report or official report of Eli Lilly.
30	Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond). 2007 Mar;31(3):494-9.
31	X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity. Chem Biol Interact. 2013 Feb 25;202(1-3):178-85.
32	ClinicalTrials.gov (NCT01990469) Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin. U.S. National Institutes of Health.
33	Clinical pipeline report, company report or official report of Emisphere Technologies Inc.
34	Clinical pipeline report, company report or official report of Merck.
35	ClinicalTrials.gov (NCT01059812) A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes. U.S. National Institutes of Health.
36	ClinicalTrials.gov (NCT02273180) Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine. U.S. National Institutes of Health.
37	Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
38	ClinicalTrials.gov (NCT00698230) Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics. U.S. National Institutes of Health.
39	ClinicalTrials.gov (NCT00252148) Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults. U.S. National Institutes of Health.
40	ClinicalTrials.gov (NCT00361738) Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin Treatment. U.S. National Institutes of Health.
41	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7701).
42	Acute effects of the beta 3-adrenoceptor agonist, BRL 35135, on tissue glucose utilisation. Br J Pharmacol. 1995 Feb;114(4):888-94.
43	ClinicalTrials.gov (NCT01681290) Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes. U.S. National Institutes of Health.
44	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013231)
45	Clinical pipeline report, company report or official report of CSIR-Central Drug Research Institute.
46	ClinicalTrials.gov (NCT02222350) Phase 2 Study of DS-8500a in Patients With Type 2 Diabetes. U.S. National Institutes of Health.
47	Clinical pipeline report, company report or official report of Emisphere Technologies.
48	ClinicalTrials.gov (NCT02405260) Add Glucokinase Activator to Target A1c. U.S. National Institutes of Health.
49	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032542)
50	ClinicalTrials.gov (NCT01968265) Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes. U.S. National Institutes of Health.
51	ClinicalTrials.gov (NCT01885260) Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes. U.S. National Institutes of Health.
52	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7411).
53	ClinicalTrials.gov (NCT01024244) A Study of LY2599506 in Patients With Type 2 Diabetes. U.S. National Institutes of Health.
54	ClinicalTrials.gov (NCT00005645) ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment. U.S. National Institutes of Health.
55	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2658).
56	ClinicalTrials.gov (NCT02119819) A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes. U.S. National Institutes of Health.
57	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000031)
58	ClinicalTrials.gov (NCT00065312) An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes. U.S. National Institutes of Health.
59	ClinicalTrials.gov (NCT02470039) Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy.
60	ClinicalTrials.gov (NCT01547897) NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria. U.S. National Institutes of Health.
61	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2811).
62	ClinicalTrials.gov (NCT00335712) Pilot Study of ONO-5129 in Patients With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
63	Discovery of p1736, a novel antidiabetic compound that improves peripheral insulin sensitivity in mice models. PLoS One. 2013 Oct 23;8(10):e77946.
64	ClinicalTrials.gov (NCT01338870) Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes. U.S. National Institutes of Health.
65	2011 Pipeline of Proximagen Group plc.
66	ClinicalTrials.gov (NCT01675154) Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia. U.S. National Institutes of Health.
67	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017743)
68	Effects of the two beta3-agonists, ZD7114 and ZD2079 on 24 hour energy expenditure and respiratory quotient in obese subjects. Int J Obes Relat Metab Disord. 2000 Dec;24(12):1553-60.
69	ClinicalTrials.gov (NCT01039597) Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis. U.S. National Institutes of Health.
70	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021204)
71	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030890)
72	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033163)
73	Clinical pipeline report, company report or official report of AstraZeneca (2011).
74	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7827).
75	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7715).
76	BMS-196085: a potent and selective full agonist of the human beta(3) adrenergic receptor. Bioorg Med Chem Lett. 2001 Dec 3;11(23):3041-4.
77	Clinical pipeline report, company report or official report of CDRI.
78	ClinicalTrials.gov (NCT01165502) Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers. U.S. National Institutes of Health.
79	ClinicalTrials.gov (NCT01956305) Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study. U.S. National Institutes of Health.
80	ClinicalTrials.gov (NCT02199899) Safety, Tolerability and Pharmacodynamics of BIIF 1149 BS in Healthy Young Male Volunteers. U.S. National Institutes of Health.
81	ClinicalTrials.gov (NCT01232036) Clinical Trial to Compare the Pharmacokinetics and Pharmacodynamics After Oral Administration of Glucophage and HL-018. U.S. National Institutes of Health.
82	ClinicalTrials.gov (NCT01524406) Safety Study of HPP593 in Subjects During and After Limb Immobilization. U.S. National Institutes of Health.
83	ClinicalTrials.gov (NCT01431521) Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008). U.S. National Institutes of Health.
84	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
85	ClinicalTrials.gov (NCT01121289) A Trial Investigating NN1218 in Subjects With Type 1 Diabetes. U.S. National Institutes of Health.
86	ClinicalTrials.gov (NCT01764425) Clinical Trial to Study the Safety Tolerability, Pharmacokinetics, Food Effect & Pharmacodynamics of a New Compound P7435 in Healthy, Overweight and/or Obese Subjects. U.S. National Institutes of Health.
87	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035270)
88	ClinicalTrials.gov (NCT02411825) Multiple Ascending Dose Study in Healthy Male Subjects. U.S. National Institutes of Health.
89	Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin Exp Immunol. 2009 Feb;155(2):156-65.
90	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003622)
91	ClinicalTrials.gov (NCT01311076) TAK-329 Glucose Clamp Study. U.S. National Institutes of Health.
92	New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. Rob M. Jones, David E. Thurston, David Rotella, Salvatore Guccione, Ana Martinez. Page(92).
93	2011 Pipeline of Zealand Pharma.
94	2011 Pipeline of Zydus Cadila Group.
95	ClinicalTrials.gov (NCT01472809) A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral ZYGK1 in Healthy Volunteers. U.S. National Institutes of Health.
96	Design and synthesis of potent, orally efficacious hydroxyethylamine derived beta-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors. J Med Chem. 2012 Nov 8;55(21):9025-44.
97	Drug information of Phenformin, 2008. eduDrugs.
98	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007468)
99	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000020)
100	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003006)
101	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
102	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001300)
103	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025707)
104	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004241)
105	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005032)
106	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001595)
107	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004537)
108	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000010)
109	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034358)
110	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017463)
111	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019065)
112	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002279)
113	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008953)
114	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004396)
115	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011538)
116	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017026)
117	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003140)
118	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023981)
119	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021799)
120	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025266)
121	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7419).
122	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021246)
123	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024090)
124	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013224)
125	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024072)
126	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036558)
127	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035670)
128	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3288).
129	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016914)
130	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027909)
131	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027910)
132	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001618)
133	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005522)
134	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028364)
135	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032059)
136	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013576)
137	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
138	2011 Pipeline of Jenrin Discovery.
139	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021066)
140	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003556)
141	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006816)
142	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016834)
143	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008690)
144	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010904)
145	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006180)
146	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006178)
147	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006177)
148	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004142)
149	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006176)
150	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013358)
151	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003002)
152	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028616)
153	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001889)
154	Studies on WF-3681, a novel aldose reductase inhibitor. IV. Effect of FR-62765, a derivative of WF-3681, on the diabetic neuropathy in rats. J Antibiot (Tokyo). 1991 Apr;44(4):441-4.
155	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011585)
156	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019200)
157	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010885)
158	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2698).
159	Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16.
160	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002923)
161	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007187)
162	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017892)
163	WF-2421, a new aldose reductase inhibitor produced from a fungus, Humicola grisea. J Antibiot (Tokyo). 1991 Feb;44(2):130-5.
164	WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
165	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
166	2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
167	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712).
168	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2030).
169	Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4070-4.
170	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612).
171	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2763).
172	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 30).
173	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2798).
174	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 105).
175	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
176	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3505).
177	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 593).
178	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 306).
179	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 307).
180	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
181	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
182	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 661).
183	PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler. Diabetes Obes Metab. 2009 May;11(5):455-9.
184	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2767).
185	KOMBIGLYZE XR tablets approved in the US for the treatment of type 2 diabetes mellitus in adults
186	ClinicalTrials.gov (NCT00499707) Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects. U.S. National Institutes of Health.